BAYER AKTIENGES ADS (BAYRY), (BAYZF) – Bayer’s Cell, gene therapies for Parkinson’s disease enters human trials
- Bayer AG (OTC: BAYRY) Parkinson’s disease stem cell therapy officially landed in the clinic, while another treatment for neurodegenerative movement disorder is recruiting patients.
- Bayer subsidiary BlueRock Therapeutics the trial will eventually have 10 participants. Patients will have dopamine-producing cells surgically implanted in a part of the brain called the putamen.
- The trial will primarily examine the safety and tolerability of DA01 cell transplantation one year after the procedure.
- Secondary objectives include evaluating the evidence for cell survival after transplant and motor effects one and two years after surgery.
- Additional data on safety and tolerability will be collected after two years.
- The company has also launched a gene therapy trial in Parkinson’s disease, this time by Asklepios BioPharmaceutical. This trial is a phase 1b.
- The AskBio trial, meanwhile, will also target the putamen with AAV gene therapy. The virus will provide a gene to stimulate expression of the GDNF gene, which has been shown in preclinical models to promote neuronal regeneration and motor recovery.
- The study has recruited ten patients since August 2020.
- Price action: BAYRY shares are down 0.25% to $ 16.15 in the last check trading session on Tuesday.
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.